Related Experiment Video

Updated: Feb 13, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.9K

Correlation between hepatic human males absent on the first (hMOF) and viral persistence in chronic hepatitis B

Liwen Chen1, Chuanwu Zhu2, Fengdi Li1

  • 11Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025 China.

Cell & Bioscience
|February 28, 2018
PubMed

Insights

Human males absent on the first (hMOF), a histone acetyltransferase, correlates with Hepatitis B virus (HBV) DNA replication in chronic hepatitis B (CHB) patients. This suggests hMOF may play a role in HBV clearance and pathogenesis.

Area of Science:

  • Hepatology
  • Virology
  • Molecular Biology

Background:

  • Chronic hepatitis B (CHB) is a significant global health issue.
  • Hepatocellular carcinoma (HCC) is a major complication of CHB.
  • The role of human males absent on the first (hMOF) in HBV replication is not fully understood.

Purpose of the Study:

  • To investigate the correlation between hepatic hMOF and HBV DNA replication in CHB patients.
  • To explore the potential role of hMOF in CHB pathogenesis and HBV clearance.

Main Methods:

  • Liver biopsy samples from CHB patients (HBeAg+ and HBeAg-) and healthy controls were analyzed.
  • Immunohistochemistry, qPCR, and Western blot were used to determine hMOF levels.
  • Correlation analysis was performed between hMOF, HBV DNA, HBsAg, and HBeAg.

Main Results:

  • A positive correlation was found between hepatic hMOF and HBV DNA in all CHB patients.
  • hMOF showed a positive correlation with HBsAg and/or HBeAg in HBeAg+ CHB patients.
  • No correlation was observed between hMOF and hepatic inflammation or fibrosis.

Conclusions:

  • Hepatic hMOF may contribute to the host's ability to clear HBV.
  • hMOF might be involved in the pathogenesis of CHB.
  • Further research into hMOF's role could offer new therapeutic strategies for CHB.
Abstract

Keywords:
ChronicityEpigenetic regulationHepatitis BViral replicationhMOF

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.9K
Generation of a Humanized Mouse Liver Using Human Hepatic Stem Cells11:44

Generation of a Humanized Mouse Liver Using Human Hepatic Stem Cells

Published on: August 29, 2016

11.5K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
255
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
609
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
312
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.9K